These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

6795 related items for PubMed ID: 24245755

  • 1. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H.
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [Abstract] [Full Text] [Related]

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 3. [Prospects for development of new antituberculous drugs].
    Tomioka H.
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [Abstract] [Full Text] [Related]

  • 4. [Prospects for the development of new antituberculous drugs putting our hopes on new drug targets].
    Tomioka H.
    Kekkaku; 2010 Nov; 85(11):815-22. PubMed ID: 21174739
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Prospects for the development of new antituberculous drugs based on the drug targets related to virulence factors interfering with host cytokine networks].
    Tomioka H.
    Kansenshogaku Zasshi; 2012 Nov; 86(6):715-22. PubMed ID: 23367846
    [Abstract] [Full Text] [Related]

  • 7. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
    Tomioka H.
    Curr Pharm Des; 2014 Nov; 20(27):4404-17. PubMed ID: 24245765
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
    Bueno RV, Braga RC, Segretti ND, Ferreira EI, Trossini GH, Andrade CH.
    Curr Pharm Des; 2014 Nov; 20(27):4474-85. PubMed ID: 24245758
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting type VII/ESX secretion systems for development of novel antimycobacterial drugs.
    Bottai D, Serafini A, Cascioferro A, Brosch R, Manganelli R.
    Curr Pharm Des; 2014 Nov; 20(27):4346-56. PubMed ID: 24245757
    [Abstract] [Full Text] [Related]

  • 12. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R, Zahra NU, Azam SS.
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [Abstract] [Full Text] [Related]

  • 13. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
    Tomioka H, Tatano Y, Sano C, Shimizu T.
    J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
    [Abstract] [Full Text] [Related]

  • 14. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
    Manina G, Pasca MR, Buroni S, De Rossi E, Riccardi G.
    Curr Med Chem; 2010 Jun; 17(27):3099-108. PubMed ID: 20629622
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F, Ventura C, Santos S, Viveiros M.
    Curr Pharm Des; 2014 Jun; 20(27):4427-54. PubMed ID: 24245762
    [Abstract] [Full Text] [Related]

  • 17. Design of novel quinoline-aminopiperidine derivatives as Mycobacterium tuberculosis (MTB) GyrB inhibitors: an in silico study.
    Wang J, Zhao C, Tu J, Yang H, Zhang X, Lv W, Zhai H.
    J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
    [Abstract] [Full Text] [Related]

  • 18. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ, Warner DF, Mizrahi V.
    Acc Chem Res; 2019 Aug 20; 52(8):2340-2348. PubMed ID: 31361123
    [Abstract] [Full Text] [Related]

  • 19. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L, Phan I, Begley DW, Clifton MC, Armour B, Dranow DM, Taylor BM, Muruthi MM, Abendroth J, Fairman JW, Fox D, Dieterich SH, Staker BL, Gardberg AS, Choi R, Hewitt SN, Napuli AJ, Myers J, Barrett LK, Zhang Y, Ferrell M, Mundt E, Thompkins K, Tran N, Lyons-Abbott S, Abramov A, Sekar A, Serbzhinskiy D, Lorimer D, Buchko GW, Stacy R, Stewart LJ, Edwards TE, Van Voorhis WC, Myler PJ.
    Tuberculosis (Edinb); 2015 Mar 20; 95(2):142-8. PubMed ID: 25613812
    [Abstract] [Full Text] [Related]

  • 20. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
    Saxena AK, Singh A.
    Curr Top Med Chem; 2019 Mar 20; 19(5):337-355. PubMed ID: 30806318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 340.